<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275117</url>
  </required_header>
  <id_info>
    <org_study_id>ALD403-CLIN-005</org_study_id>
    <nct_id>NCT02275117</nct_id>
  </id_info>
  <brief_title>A Multicenter Assessment of ALD403 in Chronic Migraine</brief_title>
  <official_title>A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alder Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alder Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess ALD403 in the prevention of migraine headache in
      chronic migraineurs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>75% Migraine Responder Rate</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>50% Migraine Responder Rate</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% Headache Responder Rate</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100% Headache Responder Rate</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100% Migraine Responder Rate</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in Monthly Headache Days, Weeks 1-12</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in Monthly Migraine Days, Weeks 1-12</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Severe Migraines</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Severe Headaches</measure>
    <time_frame>Weeks 9-12</time_frame>
    <description>The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline to Week 12 in HIT-6 Total Score</measure>
    <time_frame>Baseline to 12</time_frame>
    <description>The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as &quot;severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Headache Days</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Migraine Days</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Migraine After Dosing</measure>
    <time_frame>Baseline to Week 49 (End of Study)</time_frame>
    <description>The median number of days after dosing a participant had the next migraine using the eDiary as the recall method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monthly Migraine Attacks, Weeks 1-12</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monthly Headache Episodes, Weeks 1-12</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monthly Migraine Hours, Weeks 1-12</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monthly Headache Hours, Weeks 1-12</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication</measure>
    <time_frame>Weeks 9-12</time_frame>
    <description>The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication</measure>
    <time_frame>Weeks 9-12</time_frame>
    <description>The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">665</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>ALD403 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403 Dose Level 1 (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALD403 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403 Dose Level 2 (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALD403 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403 Dose Level 3 (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALD403 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403 Dose Level 4 (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD403</intervention_name>
    <arm_group_label>ALD403 Dose Level 1</arm_group_label>
    <arm_group_label>ALD403 Dose Level 2</arm_group_label>
    <arm_group_label>ALD403 Dose Level 3</arm_group_label>
    <arm_group_label>ALD403 Dose Level 4</arm_group_label>
    <other_name>Eptinezumab-jjmr</other_name>
    <other_name>Vyepti</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year

          -  During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days
             were assessed as migraine days with at least 5 migraine attacks as recorded in the
             eDiary

          -  Headache eDiary was completed on at least 22 of the 28 days prior to randomization

        Exclusion Criteria:

          -  Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional
             pain syndrome) or any pain syndrome that requires regular analgesia

          -  Psychiatric conditions that are uncontrolled and untreated, including conditions that
             are not controlled for a minimum of 6 months prior to screening.

          -  History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic
             tension-type headache, hypnic headache, cluster headache, hemicrania continua, new
             daily persistent headache, migraine with brainstem aura, sporadic and familial
             hemiplegic migraine

          -  Unable to differentiate migraine from other headaches

          -  Subject has received botulinum toxin for migraine or for any other medical/cosmetic
             reasons requiring injections in the head, face, or neck within 4 months prior to
             screening.

          -  Have any clinically significant concurrent medical condition

          -  Receipt of any monoclonal antibody treatment within 6 months of screening (within or
             outside a clinical trial)

          -  Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff TL Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alder Biopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserach Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Illinois</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>21310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>8963</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>2856</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Georgia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.migrainestudynow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <results_first_submitted>March 16, 2020</results_first_submitted>
  <results_first_submitted_qc>March 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <disposition_first_submitted>September 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 24, 2018</disposition_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine Disorders</keyword>
  <keyword>ALD403</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1552 participants signed the ICF, of which 665 participants met the entry criteria and were randomized into the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>300 mg ALD403</title>
          <description>Participants were randomized to receive a single 300 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="P2">
          <title>100 mg ALD403</title>
          <description>Participants were randomized to receive a single 100 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="P3">
          <title>30 mg ALD403</title>
          <description>Participants were randomized to receive a single 30 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="P4">
          <title>10 mg ALD403</title>
          <description>Participants were randomized to receive a single 10 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants were randomized to receive a single placebo IV infusion on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="133"/>
                <participants group_id="P5" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="130"/>
                <participants group_id="P5" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of Study Indication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Burden</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population includes all subjects who received investigational product or placebo. 3 participants received duplicate randomization, participants are summarized within treatment group for which they actually received treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>300 mg ALD403</title>
          <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="B2">
          <title>100 mg ALD403</title>
          <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="B3">
          <title>30 mg ALD403</title>
          <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="B4">
          <title>10 mg ALD403</title>
          <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants received a single placebo IV infusion on Day 0</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="122"/>
            <count group_id="B4" value="130"/>
            <count group_id="B5" value="121"/>
            <count group_id="B6" value="616"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="10.0"/>
                    <measurement group_id="B2" value="36.7" spread="9.4"/>
                    <measurement group_id="B3" value="35.7" spread="9.4"/>
                    <measurement group_id="B4" value="36.4" spread="10.3"/>
                    <measurement group_id="B5" value="37.2" spread="9.2"/>
                    <measurement group_id="B6" value="36.6" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="535"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="105"/>
                    <measurement group_id="B6" value="515"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="547"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="99"/>
                    <measurement group_id="B6" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Migraine Days</title>
          <description>Number of migraine days per month</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 20 days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="84"/>
                    <measurement group_id="B6" value="430"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 20 days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medication Overuse Status</title>
          <description>Investigator judgement of medication overuse status.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>75% Migraine Responder Rate</title>
        <description>Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>75% Migraine Responder Rate</title>
          <description>Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>75% Migraine Responder Rate – Week 1-12 (Modified Full Analysis Population)</non_inferiority_desc>
            <p_value>0.0330</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>24.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>75% Migraine Responder Rate – Week 1-12 (Modified Full Analysis Population)</non_inferiority_desc>
            <p_value>0.0715</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>21.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>75% Migraine Responder Rate – Week 1-12 (Modified Full Analysis Population)</non_inferiority_desc>
            <p_value>0.2013</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>75% Migraine Responder Rate – Week 1-12 (Modified Full Analysis Population)</non_inferiority_desc>
            <p_value>0.2938</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50% Migraine Responder Rate</title>
        <description>Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>50% Migraine Responder Rate</title>
          <description>Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50% Headache Responder Rate</title>
        <description>Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>50% Headache Responder Rate</title>
          <description>Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>100% Headache Responder Rate</title>
        <description>Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>100% Headache Responder Rate</title>
          <description>Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>100% Migraine Responder Rate</title>
        <description>Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>100% Migraine Responder Rate</title>
          <description>Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in Monthly Headache Days, Weeks 1-12</title>
        <description>Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Monthly Headache Days, Weeks 1-12</title>
          <description>Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="6.94"/>
                    <measurement group_id="O2" value="-8.9" spread="6.79"/>
                    <measurement group_id="O3" value="-9.2" spread="6.33"/>
                    <measurement group_id="O4" value="-7.5" spread="6.93"/>
                    <measurement group_id="O5" value="-6.9" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in Monthly Migraine Days, Weeks 1-12</title>
        <description>Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Monthly Migraine Days, Weeks 1-12</title>
          <description>Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="7.00"/>
                    <measurement group_id="O2" value="-7.7" spread="6.87"/>
                    <measurement group_id="O3" value="-7.9" spread="6.38"/>
                    <measurement group_id="O4" value="-6.7" spread="6.80"/>
                    <measurement group_id="O5" value="-5.6" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Severe Migraines</title>
        <description>The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Severe Migraines</title>
          <description>The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>percentage of severe migraines</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="29.47"/>
                    <measurement group_id="O2" value="-15.9" spread="27.38"/>
                    <measurement group_id="O3" value="-17.2" spread="26.98"/>
                    <measurement group_id="O4" value="-16.1" spread="29.80"/>
                    <measurement group_id="O5" value="-9.7" spread="27.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Severe Headaches</title>
        <description>The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12</description>
        <time_frame>Weeks 9-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Severe Headaches</title>
          <description>The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>percentage of severe headaches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.91" spread="25.800"/>
                    <measurement group_id="O2" value="-10.36" spread="28.004"/>
                    <measurement group_id="O3" value="-12.17" spread="30.197"/>
                    <measurement group_id="O4" value="-11.42" spread="30.517"/>
                    <measurement group_id="O5" value="-6.48" spread="27.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline to Week 12 in HIT-6 Total Score</title>
        <description>The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as &quot;severe&quot;.</description>
        <time_frame>Baseline to 12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline to Week 12 in HIT-6 Total Score</title>
          <description>The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as &quot;severe&quot;.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>percentage of HIT-6 total score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.4"/>
                    <measurement group_id="O2" value="-43.4"/>
                    <measurement group_id="O3" value="-34.9"/>
                    <measurement group_id="O4" value="-34.8"/>
                    <measurement group_id="O5" value="-28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Headache Days</title>
        <description>Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Headache Days</title>
          <description>Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>percentage of headache days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.12" spread="31.481"/>
                    <measurement group_id="O2" value="-43.09" spread="33.912"/>
                    <measurement group_id="O3" value="-44.37" spread="28.620"/>
                    <measurement group_id="O4" value="-37.20" spread="34.112"/>
                    <measurement group_id="O5" value="-34.02" spread="30.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Migraine Days</title>
        <description>Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Migraine Days</title>
          <description>Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>percentage of migraine days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.88" spread="41.243"/>
                    <measurement group_id="O2" value="-46.79" spread="40.983"/>
                    <measurement group_id="O3" value="-46.74" spread="36.588"/>
                    <measurement group_id="O4" value="-40.80" spread="40.133"/>
                    <measurement group_id="O5" value="-35.37" spread="41.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Migraine After Dosing</title>
        <description>The median number of days after dosing a participant had the next migraine using the eDiary as the recall method</description>
        <time_frame>Baseline to Week 49 (End of Study)</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Migraine After Dosing</title>
          <description>The median number of days after dosing a participant had the next migraine using the eDiary as the recall method</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monthly Migraine Attacks, Weeks 1-12</title>
        <description>The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Migraine Attacks, Weeks 1-12</title>
          <description>The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Migraine Attacks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="5.4"/>
                    <measurement group_id="O2" value="-6.5" spread="4.9"/>
                    <measurement group_id="O3" value="-6.9" spread="5.0"/>
                    <measurement group_id="O4" value="-6.2" spread="5.2"/>
                    <measurement group_id="O5" value="-5.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monthly Headache Episodes, Weeks 1-12</title>
        <description>The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Headache Episodes, Weeks 1-12</title>
          <description>The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Headache Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="5.54"/>
                    <measurement group_id="O2" value="-8.0" spread="5.37"/>
                    <measurement group_id="O3" value="-8.3" spread="5.55"/>
                    <measurement group_id="O4" value="-7.3" spread="5.37"/>
                    <measurement group_id="O5" value="-7.0" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monthly Migraine Hours, Weeks 1-12</title>
        <description>Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Migraine Hours, Weeks 1-12</title>
          <description>Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Migraine Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.9" spread="100.34"/>
                    <measurement group_id="O2" value="-64.2" spread="114.58"/>
                    <measurement group_id="O3" value="-63.1" spread="84.56"/>
                    <measurement group_id="O4" value="-49.2" spread="103.83"/>
                    <measurement group_id="O5" value="-34.9" spread="100.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monthly Headache Hours, Weeks 1-12</title>
        <description>Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.</description>
        <time_frame>Weeks 1-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Headache Hours, Weeks 1-12</title>
          <description>Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>Headache Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.9" spread="101.53"/>
                    <measurement group_id="O2" value="-60.9" spread="114.77"/>
                    <measurement group_id="O3" value="-62.9" spread="81.89"/>
                    <measurement group_id="O4" value="-47.5" spread="102.84"/>
                    <measurement group_id="O5" value="-38.7" spread="99.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication</title>
        <description>The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.</description>
        <time_frame>Weeks 9-12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication</title>
          <description>The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.</description>
          <units>percentage of acute medication migraines</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.43" spread="39.121"/>
                    <measurement group_id="O2" value="-10.36" spread="43.890"/>
                    <measurement group_id="O3" value="-4.44" spread="37.746"/>
                    <measurement group_id="O4" value="-10.03" spread="40.460"/>
                    <measurement group_id="O5" value="-9.60" spread="37.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication</title>
        <description>The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.</description>
        <time_frame>Weeks 9-12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication</title>
          <description>The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>percentage of acute medication headaches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.98" spread="34.144"/>
                    <measurement group_id="O2" value="-3.27" spread="34.419"/>
                    <measurement group_id="O3" value="1.52" spread="30.013"/>
                    <measurement group_id="O4" value="-3.14" spread="32.853"/>
                    <measurement group_id="O5" value="-3.42" spread="32.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12</title>
        <description>The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg ALD403</title>
            <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>100 mg ALD403</title>
            <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>30 mg ALD403</title>
            <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>10 mg ALD403</title>
            <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a single placebo IV infusion on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12</title>
          <description>The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.</description>
          <population>Modified Full Analysis Population - Randomized participants who received investigational product or placebo, excluding participants from a site that was terminated by the Sponsor.</population>
          <units>SF-36 Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="8.7"/>
                    <measurement group_id="O2" value="50.6" spread="7.8"/>
                    <measurement group_id="O3" value="51.1" spread="7.6"/>
                    <measurement group_id="O4" value="50.3" spread="8.4"/>
                    <measurement group_id="O5" value="50.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="5.0"/>
                    <measurement group_id="O2" value="51.2" spread="8.3"/>
                    <measurement group_id="O3" value="52.5" spread="7.2"/>
                    <measurement group_id="O4" value="51.3" spread="7.9"/>
                    <measurement group_id="O5" value="51.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="9.5"/>
                    <measurement group_id="O2" value="45.2" spread="9.3"/>
                    <measurement group_id="O3" value="45.6" spread="9.3"/>
                    <measurement group_id="O4" value="44.9" spread="9.9"/>
                    <measurement group_id="O5" value="44.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="7.2"/>
                    <measurement group_id="O2" value="48.9" spread="9.3"/>
                    <measurement group_id="O3" value="49.9" spread="7.7"/>
                    <measurement group_id="O4" value="47.9" spread="9.9"/>
                    <measurement group_id="O5" value="48.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain -Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="9.5"/>
                    <measurement group_id="O2" value="42.7" spread="9.6"/>
                    <measurement group_id="O3" value="44.5" spread="9.9"/>
                    <measurement group_id="O4" value="43.0" spread="9.6"/>
                    <measurement group_id="O5" value="42.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="8.4"/>
                    <measurement group_id="O2" value="46.5" spread="9.9"/>
                    <measurement group_id="O3" value="48.1" spread="9.2"/>
                    <measurement group_id="O4" value="46.6" spread="9.3"/>
                    <measurement group_id="O5" value="46.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="9.2"/>
                    <measurement group_id="O2" value="50.7" spread="9.8"/>
                    <measurement group_id="O3" value="50.9" spread="8.7"/>
                    <measurement group_id="O4" value="51.1" spread="9.5"/>
                    <measurement group_id="O5" value="50.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" spread="8.7"/>
                    <measurement group_id="O2" value="50.7" spread="10.2"/>
                    <measurement group_id="O3" value="50.7" spread="9.2"/>
                    <measurement group_id="O4" value="52.7" spread="9.8"/>
                    <measurement group_id="O5" value="50.6" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="8.9"/>
                    <measurement group_id="O2" value="50.1" spread="10.6"/>
                    <measurement group_id="O3" value="49.6" spread="9.8"/>
                    <measurement group_id="O4" value="49.4" spread="10.1"/>
                    <measurement group_id="O5" value="48.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="7.8"/>
                    <measurement group_id="O2" value="50.9" spread="10.5"/>
                    <measurement group_id="O3" value="50.6" spread="11.3"/>
                    <measurement group_id="O4" value="50.7" spread="10.6"/>
                    <measurement group_id="O5" value="51.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="10.8"/>
                    <measurement group_id="O2" value="46.3" spread="10.1"/>
                    <measurement group_id="O3" value="46.8" spread="10.7"/>
                    <measurement group_id="O4" value="45.5" spread="10.4"/>
                    <measurement group_id="O5" value="45.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="8.1"/>
                    <measurement group_id="O2" value="48.7" spread="10.1"/>
                    <measurement group_id="O3" value="49.5" spread="9.0"/>
                    <measurement group_id="O4" value="47.7" spread="9.8"/>
                    <measurement group_id="O5" value="48.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="9.1"/>
                    <measurement group_id="O2" value="49.4" spread="9.6"/>
                    <measurement group_id="O3" value="49.4" spread="9.7"/>
                    <measurement group_id="O4" value="49.8" spread="10.3"/>
                    <measurement group_id="O5" value="50.9" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="8.2"/>
                    <measurement group_id="O2" value="50.2" spread="9.0"/>
                    <measurement group_id="O3" value="51.2" spread="7.2"/>
                    <measurement group_id="O4" value="50.9" spread="8.4"/>
                    <measurement group_id="O5" value="51.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="8.4"/>
                    <measurement group_id="O2" value="52.0" spread="9.3"/>
                    <measurement group_id="O3" value="51.8" spread="9.5"/>
                    <measurement group_id="O4" value="51.4" spread="9.5"/>
                    <measurement group_id="O5" value="50.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" spread="8.8"/>
                    <measurement group_id="O2" value="50.8" spread="10.1"/>
                    <measurement group_id="O3" value="51.2" spread="9.5"/>
                    <measurement group_id="O4" value="52.2" spread="9.5"/>
                    <measurement group_id="O5" value="52.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="9.4"/>
                    <measurement group_id="O2" value="50.9" spread="9.7"/>
                    <measurement group_id="O3" value="50.5" spread="9.6"/>
                    <measurement group_id="O4" value="50.4" spread="9.9"/>
                    <measurement group_id="O5" value="50.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="9.0"/>
                    <measurement group_id="O2" value="50.5" spread="9.7"/>
                    <measurement group_id="O3" value="50.7" spread="9.4"/>
                    <measurement group_id="O4" value="51.3" spread="9.3"/>
                    <measurement group_id="O5" value="51.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="8.4"/>
                    <measurement group_id="O2" value="46.1" spread="8.4"/>
                    <measurement group_id="O3" value="47.1" spread="7.7"/>
                    <measurement group_id="O4" value="46.1" spread="8.3"/>
                    <measurement group_id="O5" value="45.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="6.8"/>
                    <measurement group_id="O2" value="49.0" spread="8.6"/>
                    <measurement group_id="O3" value="50.1" spread="7.0"/>
                    <measurement group_id="O4" value="48.8" spread="8.5"/>
                    <measurement group_id="O5" value="48.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 49 (end of study)</time_frame>
      <desc>3 participants received duplicate randomization, participants are summarized within treatment group for which they actually received treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>300 mg ALD403</title>
          <description>Participants received a single 300 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="E2">
          <title>100 mg ALD403</title>
          <description>Participants received a single 100 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="E3">
          <title>30 mg ALD403</title>
          <description>Participants received a single 30 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="E4">
          <title>10 mg ALD403</title>
          <description>Participants received a single 10 mg IV infusion of ALD403 on Day 0</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants received a single placebo IV infusion on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vaginal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance-induced mood disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Email contact via</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+4536301311</phone>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

